Alpha Tau Medical (NASDAQ:DRTS) Stock Price Down 0.3% – Time to Sell?

Alpha Tau Medical Ltd. (NASDAQ:DRTS)’s share price fell 0.3% during mid-day trading on Thursday . The company traded as low as $3.01 and last traded at $3.06. 43,453 shares were traded during trading, a decline of 12% from the average session volume of 49,258 shares. The stock had previously closed at $3.07.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $9.00 price objective on shares of Alpha Tau Medical in a research note on Tuesday, April 29th.

Alpha Tau Medical Stock Performance

The firm has a market cap of $259.55 million, a price-to-earnings ratio of -6.65 and a beta of 0.99. The company has a quick ratio of 5.81, a current ratio of 5.81 and a debt-to-equity ratio of 0.10. The stock has a fifty day moving average price of $3.03 and a 200-day moving average price of $2.99.

Alpha Tau Medical (NASDAQ:DRTS) last announced its quarterly earnings data on Monday, May 19th. The company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.02. On average, analysts expect that Alpha Tau Medical Ltd. will post -0.45 earnings per share for the current fiscal year.

Institutional Trading of Alpha Tau Medical

Large investors have recently made changes to their positions in the stock. XTX Topco Ltd purchased a new position in shares of Alpha Tau Medical in the 1st quarter worth about $53,000. Renaissance Technologies LLC grew its position in shares of Alpha Tau Medical by 188.7% in the 4th quarter. Renaissance Technologies LLC now owns 41,000 shares of the company’s stock worth $127,000 after acquiring an additional 26,800 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of Alpha Tau Medical by 112.6% in the 4th quarter. Northern Trust Corp now owns 48,666 shares of the company’s stock worth $151,000 after purchasing an additional 25,770 shares during the last quarter. Finally, Kovitz Investment Group Partners LLC raised its stake in Alpha Tau Medical by 601.4% during the 1st quarter. Kovitz Investment Group Partners LLC now owns 226,320 shares of the company’s stock valued at $568,000 after acquiring an additional 194,055 shares in the last quarter. Institutional investors and hedge funds own 2.65% of the company’s stock.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.